Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
Schoenfelder K, Schuh H, Pfister F, Kraemer J, Eisenberger U, Skuljec J, Hackert J, Ruck T, Pfeuffer S, Fleischer M, Gaeckler A, Hagenacker T, Kribben A, Meuth SG, Kleinschnitz C, Pul R (2021)
Publication Type: Journal article
Publication year: 2021
Journal
DOI: 10.1177/13524585211022719
Abstract
Background: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine. Objective and Results: Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle. Conclusion: Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.
Authors with CRIS profile
Additional Organisation(s)
Involved external institutions
Germany (DE)How to cite
APA:
Schoenfelder, K., Schuh, H., Pfister, F., Kraemer, J., Eisenberger, U., Skuljec, J.,... Pul, R. (2021). Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment. Multiple sclerosis journal. https://doi.org/10.1177/13524585211022719
MLA:
Schoenfelder, Kristina, et al. "Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment." Multiple sclerosis journal (2021).
BibTeX: Download